BACKGROUND: Pulmonary vein isolation (PVI) using cryoballoon ablation (PVI-C) is increasingly performed as a first-line strategy for the treatment of patients with persistent atrial fibrillation (PersAF); however, follow-up data and predictors of procedural success are lacking. OBJECTIVE: To study the efficacy of PVI-C in patients with PersAF, focusing on predictors of procedural success. METHODS: By retrospective review, 148 consecutive patients with PersAF who underwent PVI-C were analyzed. The impact of several variables on outcome was evaluated in univariate and multivariate analyses and Cox proportional hazards regression models. RESULTS: After a mean follow-up of 19.2±10.9 months, 75 (50.7%) patients remained arrhythmia-free without the need for antiarrhythmic drug therapy. Patients with a normal left atrial volume index (LAVI) achieved a 71.0% arrhythmia-free survival. LAVI was the most powerful predictor of procedural success. CONCLUSIONS: Arrhythmia-free survival after PVI-C in select patients with PersAF are promising. Moreover, LAVI is a valuable measurement to help guide ablation strategy and predict outcome when using cryoballoon ablation.
BACKGROUND: Pulmonary vein isolation (PVI) using cryoballoon ablation (PVI-C) is increasingly performed as a first-line strategy for the treatment of patients with persistent atrial fibrillation (PersAF); however, follow-up data and predictors of procedural success are lacking. OBJECTIVE: To study the efficacy of PVI-C in patients with PersAF, focusing on predictors of procedural success. METHODS: By retrospective review, 148 consecutive patients with PersAF who underwent PVI-C were analyzed. The impact of several variables on outcome was evaluated in univariate and multivariate analyses and Cox proportional hazards regression models. RESULTS: After a mean follow-up of 19.2±10.9 months, 75 (50.7%) patients remained arrhythmia-free without the need for antiarrhythmic drug therapy. Patients with a normal left atrial volume index (LAVI) achieved a 71.0% arrhythmia-free survival. LAVI was the most powerful predictor of procedural success. CONCLUSIONS: Arrhythmia-free survival after PVI-C in select patients with PersAF are promising. Moreover, LAVI is a valuable measurement to help guide ablation strategy and predict outcome when using cryoballoon ablation.
Authors: Roberto M Lang; Luigi P Badano; Victor Mor-Avi; Jonathan Afilalo; Anderson Armstrong; Laura Ernande; Frank A Flachskampf; Elyse Foster; Steven A Goldstein; Tatiana Kuznetsova; Patrizio Lancellotti; Denisa Muraru; Michael H Picard; Ernst R Rietzschel; Lawrence Rudski; Kirk T Spencer; Wendy Tsang; Jens-Uwe Voigt Journal: J Am Soc Echocardiogr Date: 2015-01 Impact factor: 5.251
Authors: Teresa S M Tsang; Walter P Abhayaratna; Marion E Barnes; Yoko Miyasaka; Bernard J Gersh; Kent R Bailey; Stephen S Cha; James B Seward Journal: J Am Coll Cardiol Date: 2006-02-09 Impact factor: 24.094
Authors: Julia Vogler; Stephan Willems; Arian Sultan; Doreen Schreiber; Jakob Lüker; Helge Servatius; Benjamin Schäffer; Julia Moser; Boris A Hoffmann; Daniel Steven Journal: J Am Coll Cardiol Date: 2015-12-22 Impact factor: 24.094